Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company focusing on neurodegenerative diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company, which specializes in improving mitochondrial health and protecting neuronal function, will present virtually on September 9, 2024, at 7:00 am EST.
Clene's management will deliver a presentation and host one-on-one investor meetings during the conference. Investors interested in scheduling meetings are advised to contact their H.C. Wainwright representative. A webcast of the presentation will be accessible through the 'Events' section of Clene's website, with an additional online registration option available for viewing.
Clene Inc. (Nasdaq: CLNN), un'azienda biofarmaceutica in fase clinica che si concentra sulle malattie neurodegenerative, ha annunciato la sua partecipazione al 26° Congresso Annuale di Investimento Globale H.C. Wainwright. L'azienda, specializzata nel migliorare la salute mitocondriale e proteggere la funzione neuronale, presenterà virtualmente il 9 settembre 2024, alle 7:00 AM EST.
Il management di Clene terrà una presentazione e ospiterà incontri individuali con gli investitori durante la conferenza. Gli investitori interessati a pianificare incontri sono invitati a contattare il loro rappresentante H.C. Wainwright. Una trasmissione in streaming della presentazione sarà accessibile attraverso la sezione 'Eventi' del sito web di Clene, con un'ulteriore opzione di registrazione online disponibile per la visione.
Clene Inc. (Nasdaq: CLNN), una empresa biofarmacéutica en etapa clínica que se enfoca en enfermedades neurodegenerativas, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversión H.C. Wainwright. La empresa, que se especializa en mejorar la salud mitocondrial y proteger la función neuronal, presentará de forma virtual el 9 de septiembre de 2024, a las 7:00 AM EST.
La gerencia de Clene realizará una presentación y albergará reuniones individuales con inversionistas durante la conferencia. Se aconseja a los inversionistas interesados en programar reuniones que contacten a su representante de H.C. Wainwright. Una transmisión en vivo de la presentación estará disponible a través de la sección 'Eventos' en el sitio web de Clene, con una opción adicional de registro en línea para ver.
클레네 주식회사 (Nasdaq: CLNN)는 신경퇴행성 질환에 초점을 맞춘 임상 단계의 생명공학 회사로, H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 미토콘드리아 건강 개선과 신경 세포 기능 보호를 전문으로 하는 이 회사는 2024년 9월 9일 오전 7시 EST에 가상으로 발표할 예정입니다.
클레네의 경영진은 발표를 하며 컨퍼런스 기간 동안 일대일 투자자 미팅을 주최할 것입니다. 미팅 일정을 잡고 싶은 투자자들은 H.C. 웨인라이트 대표에게 연락할 것을 권장합니다. 발표의 웹캐스트는 클레네 홈페이지의 '이벤트' 섹션을 통해 접근 가능하며, 시청을 위한 추가 온라인 등록 옵션도 제공됩니다.
Clene Inc. (Nasdaq: CLNN), une entreprise bio-pharmaceutique en phase clinique axée sur les maladies neurodégénératives, a annoncé sa participation à la 26e Conférence Annuelle d'Investissement Mondial H.C. Wainwright. L'entreprise, spécialisée dans l'amélioration de la santé mitochondriale et la protection de la fonction neuronale, présentera virtuellement le 9 septembre 2024, à 7h00 EST.
La direction de Clene fera une présentation et organisera des réunions individuelles avec les investisseurs durant la conférence. Les investisseurs intéressés à planifier des réunions sont priés de contacter leur représentant H.C. Wainwright. Un webinaire de la présentation sera accessible dans la section 'Événements' du site Web de Clene, avec une option d'inscription en ligne supplémentaire disponible pour visionner.
Clene Inc. (Nasdaq: CLNN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf neurodegenerative Erkrankungen spezialisiert hat, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt. Das Unternehmen, das auf die Verbesserung der mitochondrialen Gesundheit und den Schutz der neuronalen Funktion spezialisiert ist, wird am 9. September 2024 um 7:00 Uhr EST virtuell präsentieren.
Das Management von Clene wird eine Präsentation halten und während der Konferenz Einzelgespräche mit Investoren führen. Investoren, die an der Planung von Meetings interessiert sind, werden gebeten, ihren Vertreter von H.C. Wainwright zu kontaktieren. Ein Webcast der Präsentation wird im Bereich 'Veranstaltungen' auf der Website von Clene zugänglich sein, mit einer zusätzlichen Online-Registrierungsoption zum Ansehen.
- None.
- None.
SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings.
Date: September 9, 2024
Time of Presentation: 7:00 am EST
Format: Virtual Presentation
1x1 Meetings: Please contact your H.C. Wainwright representative
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Contacts:
| Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 | Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856 |
FAQ
When is Clene Inc. (CLNN) presenting at the H.C. Wainwright Global Investment Conference?
What is the format of Clene's (CLNN) presentation at the H.C. Wainwright conference?
How can investors access Clene's (CLNN) presentation at the H.C. Wainwright conference?
What are the main focus areas of Clene Inc. (CLNN)?
Will Clene (CLNN) be hosting one-on-one meetings at the H.C. Wainwright conference?
